Toho : New Structure after changing to a Company with Audit and Supervisory Committee
May 27, 2016 at 08:31 am
Share
898bc6af-f5ec-4ad8-a526-9f2dc92f38c9.pdf
To whom it may concern:
Company Name
TOHO HOLDINGS CO., LTD.
Corporate Representative
Norio Hamada, President and Representative Director
(First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:
Makoto Kawamura, Joint General Manager, Corporate Planning Division and General Manager, Public and Investor Relations Office
(TEL: 03-6838-2803)
May 11, 2016
New Structure after changing to a Company with Audit and Supervisory Committee
TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Norio Hamada) hearby announces that it resolved informally, as mentioned below, at the Board of Directors' meeting which was held today, on the premise of approval at the 68th annual meeting of stockholders to be held in late June 2016, the Directors, excluding those who are audit and supervisory committee members, and those Directors who are audit and supervisory committee members, hereinafter called "audit and supervisory committee members," after changing to a company with audit and supervisory committee.
Candidates for the Directors, excluding those who are audit and supervisory committee members
(to be discussed at the 68th annual meeting of stockholders)
Name
Post to be appointed
Current post
Norio Hamada
Representative Director
President and Representative Director
Hiroyuki Kono
Representative Director
Chairman of the Board and Representative Director
Toshio Honma
Director
Vice President and Director
Mitsuo Morikubo
Director
Executive Managing Director
Mamoru Ogino
Director
Executive Managing Director
Katsuya Kato
Director
Executive Managing Director
Takeo Matsutani
Director
Director
Takaaki Matsutani
Director
Director and Senior Adviser
Hiromi Edahiro
Director
Director
Atsuko Naitou
Director
Director
Atsushi Udoh
Director
Corporate Officer
Akira Umada
Director
Corporate Officer
Kazuo Takeda
Director
Full-time Auditor (Outside)
Shunsuke Watanabe
Director (Outside)
Director (Outside)
Shosaku Murayama
Director (Outside)
Director (Outside)
Toru Nagasawa
Director (Outside)
Director (Outside)
Mr. Norio Hamada and Mr. Hiroyuki Kono are planned to be further appointed as Representative Directors at the Board of Directors' meeting to be held after the 68th annual meeting of stockholders, after they are appointed as Directors excluding those who are audit and supervisory committee members, at the same annual meeting of stockholders.
Candidates for Directors who are audit and supervisory committee members
(to be discussed at the 68th annual meeting of stockholders)
Name
Post to be appointed
Current post
Hideyuki Shimizu
Audit and supervisory committee member
Full-time Auditor
Sachio Tokaji
Audit and supervisory committee member(Outside)
―
Koji Nakamura
Audit and supervisory committee member(Outside)
―
Retiring members (to retire at the end of the 68th annual meeting of stockholders) Full-time Auditor Hideyuki Shimizu
Toho Holdings Co. Ltd. published this content on 11 May 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 27 May 2016 07:30:04 UTC.
Original documenthttp://www.tohohd.co.jp/en/news/20160511-2_E.pdf
Public permalinkhttp://www.publicnow.com/view/D84C3BB72BAD420F7285CF68AF9F77F8440343F3
Toho Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical wholesale business. The Company operates through five business segments. The Pharmaceutical Wholesale segment purchases pharmaceuticals and medical-related products from pharmaceutical manufacturers and sells them to hospitals, clinics and dispensing pharmacies. It is also engaged in the provision of data processing system and rental of real estate. The Dispensing Pharmacy segment is engaged in the management of insurance dispensing pharmacies and dispensing pharmacies. The Pharmaceutical Manufacture and Sale segment is engaged in the manufacture and sale of generic drugs and contract manufacturing of injectable drugs. The Clinical Trial Facility Support segment is engaged in the provision of support for clinical trial facilities. The Information Equipment Sales segment is engaged in the planning and sale of information processing equipment.